Orlistat is used to treat obesity and help in weight loss. Orlistat is to be used along with a low-calorie diet and regular physical exercise. Obesity is a common condition associated with excessive body fat, which in turn increases the risk of other health problems such as diabetes, high blood pressure, certain cancers, and heart disease. Intake of more calories than you burn by exercise or daily activities results in obesity.
Orlistat contains Orlistat, which works in the small intestine and stomach and prevents the action of enzymes that break down fat, which is absorbed by the body. Orlistat decreases the absorption of fat from the food you eat. Thus, fat passes through the gut and is excreted in the faeces, which makes the body unable to use fat as a source of energy or convert it into fat tissue. Thereby, Orlistat helps in weight loss.
Take Orlistat as prescribed by your doctor. You are advised to take Orlistat for as long as your doctor has prescribed it for you based on your medical condition. Some people may experience soft stools, sudden bowel motions, flatulence (gas) with or without oily spotting, oily or fatty stools, stomach pain, stool incontinence (involuntary leakage of stools), and runny or liquid stools. Most of these side effects of Orlistat do not require medical attention and gradually resolve over time. However, if the side effects persist, please consult your doctor.
If you are allergic to Orlistat or any other medicines, please tell your doctor. Avoid taking Orlistat if you are pregnant or planning for pregnancy, as it may cause fetal harm. It is not known whether Orlistat is excreted in human milk. Therefore, please consult a doctor if you are a breastfeeding woman. Orlistat is not recommended for children below 18 years of age, as the safety and effectiveness were not established. You are advised to take a multivitamin containing fat-soluble vitamins such as A, D, E, and K at bedtime as Orlistat may reduce the absorption of certain vitamins in the body.
ContraindicationsThis medication does not contraindicate any drug called anticonvulsants (such as phenytoin), oral contraceptives (such as alfuzosin and terazosin), metformin, metoprolol, nitrates (such as isosorbide dinitrate and isosorbide mononitrate, itraconazole), alpha-blockers (such as doxazosin or tamsulosin), and antifungals (such as posologyin, miconazole). These medications have also not been associated with an increased risk of any of the following diseases such as myitis, bacterial vaginosis, dysenteriaion, and endometriosis. Because Orlistat may reduce the absorption of certain vitamins in the body, it is not recommended for these patients. If you experience sudden bowel movements (e.g., bowel motions, flatulence, gas), or involuntary leakage of stools, consult a doctor immediately. Orlistat may cause stomaches, cramps, and sprains in some people. Therefore, avoid sharing or sharing any food with the patients. Avoid engaging in activities that may cause sudden bowel movements, including activities such as lying down or lying down, unless a doctor has said it is safe to do so. If you are a woman, you are not recommended to take Orlistat while you are pregnant. Orlistat may affect the developing fetus. However, if you are pregnant, the potential side effects of Orlistat may be serious. Tell your doctor if you are pregnant or plan to become pregnant.
Objective:To compare the safety and tolerability of a three-month combination of diet and active ingredient (XENICAL) capsules versus conventional capsules or a capsule capsule, with respect to the occurrence of weight loss and the pharmacokinetics.
Study Design:The current multicenter, open-label, single-center, double-blind, randomised, crossover design.
Patients:Applying to the first 120 capsules of 60 capsules/day, patients were randomised to 120 capsules or 60 capsules of each other on day 1 of the course of treatment. At 12 weeks and 90 days, participants were monitored and observed throughout the course of the study. Patients with a body mass index (BMI) of ≥ or equal to 30 kg/m2 at time of enrolment were excluded from the study.
Follow-Up Period:During treatment, the study subjects received either 30 capsules of 60 capsules or 60 capsules of each other at the beginning of treatment. The first 120 capsules of each capsule/day (administered on day 1 of the course of treatment) were taken for 2 weeks. The remaining 120 capsules were taken for 1 year until all patients completed the 120 capsules.
Safety Profile:Safety was defined as the occurrence of ≥ 2 ≥ 3 or ≥ 4 ≥ 5 adverse events, according to the Clinical Global Impressions tool (CGI-II), during the first 12 weeks of treatment.
Inclusion and Exclusion Criteria:Patients with a body mass index (BMI) of ≥ or equal to 30 kg/m2 at time of enrolment, and a history of obesity, such as a history of heart disease, diabetes mellitus, or thyroid disease, or if they had a history of pancreatitis, or other cardiovascular disease, were excluded. Patients with a BMI of ≥ or equal to 30 kg/m2 at time of enrolment, or those who had a history of heart disease, diabetes, or thyroid disease, or if they were not taking oral contraceptives, were also excluded.
Patients in whom the pharmacokinetic profile of each capsule showed a significant decrease in the elimination half-life (t½), with or without a significant increase in the elimination half-life (t½ ≥ 2.5 hr), were also excluded from the study.
Patients with a history of malignant or benign tumor or malignancy, severe liver impairment, uncontrolled diabetes mellitus, or hypertension.
All subjects were also excluded from the study if they were on any active medication or were taking any other pharmacological agent.
Dosage:The daily dose of each capsule was calculated by the investigator using a modified dose algorithm based on body weight. The maximum daily dose was calculated by the investigator. The pharmacokinetic parameters of each capsule were measured at the beginning of the study and at each time-point. The pharmacokinetic parameters of each capsule were calculated at the start of treatment and during each follow-up period (i.e., after 2 weeks of treatment).
If any of the above-mentioned adverse events were severe or possibly serious, they were referred to the Committee on Adverse Reactions (COAR) of the FDA for an appropriate emergency use.
Patients were informed about the potential benefits and risks of the study, that they would be treated with this product, and that the benefits of the study would not be permanent.
The maximum daily dose of each capsule was calculated by the investigator.
Safety was defined as the occurrence of ≥ 2 ≥ 3 or ≥ 4 ≥ 5 adverse events, according to the CSAI-II. If any of the above-mentioned adverse events were severe or possibly serious, they were referred to the Committee on Adverse Reactions (COAR).
You must complete an online form outlining your medical history, weight, and other medications.
A pharmacy will then confirm within 48 hours whether your application for an Orlistat prescription has been approved.
The exact eligibility criteria for an Orlistat prescription are kept confidential for patient safety.
Lipase inhibitors like Xenical and Alli can lead to weight loss of 4-8% after one year, alongside changes to diet and lifestyle.
They’re also well-tolerated, with human clinical trials indicating less than 10% of people stop taking the medication due to adverse effects.
However, all medications come with risks and rewards, and not everyone is suitable for weight-loss pills like Orlistat.
Deciding to start a new medication is a highly personal choice. So, ultimately, it depends on whether you believe it’s the best decision for your health going forward.
All weight-loss medications are designed to be taken alongside changes to your lifestyle. Without this, the effects of the drug will not last, and you’ll likely regain any weight you lose in the future.
Second Nature currently provides Mounjaro as part of our.
Why should you choose Second Nature over other medication providers if you’ve decided to try Mounjaro (assuming you’re eligible)?
For peace of mind.
Second Nature has worked with the NHS for over 6 years providing weight-loss programmes across the UK.
While our Mounjaro weight-loss programme is private and not currently used by the NHS, we’ve built the programmes focusing on scientific evidence, patient safety, and data security.
We hope that our 6+ years of working with the NHS and building a track record of effective weight-loss results will give you peace of mind to give us a try.
How does Mounjaro work?Orlistat works in your system to reduce the absorption of about 25% of the calories from fat.
It is available as a take-back option after weight loss, and can be used to help people with obesity continue their normal diet.
It is available as a take-back option before another medication is thought to be ineffective.
Note:Second Nature only supports weight-loss effects directly from your body, so you should still try to take the medication as part of your Mounjaro weight-loss regime.
However, you should never take Mounjaro if you are not using all available-grade anticoagulants or other weight-loss medications.
If you develop any signfic of a adverse effect while taking Mounjaro, contact your doctor or pharmacist.
Warnings:
Key Takeaways:
Lipase Inhibitor (e.g., Orlistat, Or-Xenical)
Reduces Fat Absorption (e.g., Phentermine/Qsymia)
Lipase Inhibitor (e.g., Alli)
Contains Orlistat (e.g., Alli XR), Or-Xenical (e.g., Alli XR XR), orlistat (e.g., Alli L-XR)
This study was conducted with the following grant sponsors:
Biogen, Germany:
The author(s) received no specific grant support for this work. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
Funding:
Michele R. Hoeper, MD; Hoehn Hoe, MD, and Paul L. Wiese, MD, PhD, contributed equally to this work.Conflict of interest:
The author(s) received no specific funding for this work.
The following chart and tables are examples of the results obtained from the study design, study setting, and outcome measures. The following are the flow-through tables and figures for the main outcome measures:
Figure 1.Treatment plans. (A) Patients with obesity or type 2 diabetes, either in the initial or follow-up phase of the trial, had to receive Orlistat in addition to standard care (eg, diet, exercise, weight loss) or lifestyle intervention (eg, weight control).
Figure 2.Prevalence and incidence of obesity and type 2 diabetes in the first year of the study. (A) Prevalence of obesity or type 2 diabetes in the first year of the study, (B) Prevalence of type 2 diabetes in the first year of the study, (C) Prevalence of type 2 diabetes in the first year of the study, and (D) Prevalence of obesity or type 2 diabetes in the first year of the study. BMI, body mass index.
Figure 3.Prevalence of type 2 diabetes in the first year of the study. (A) Prevalence of type 2 diabetes in the first year of the study, (B) Prevalence of type 2 diabetes in the first year of the study, (C) Prevalence of type 2 diabetes in the first year of the study, and (D) Prevalence of type 2 diabetes in the first year of the study.
Figure 4.Prevalence of obesity and type 2 diabetes in the first year of the study. (A) Prevalence of obesity or type 2 diabetes in the first year of the study, (B) Prevalence of type 2 diabetes in the first year of the study, and (C) Prevalence of obesity or type 2 diabetes in the first year of the study.
Figure 5.(A) Prevalence of type 2 diabetes in the first year of the study, (B) Prevalence of type 2 diabetes in the first year of the study, and (C) Prevalence of obesity or type 2 diabetes in the first year of the study.
Figure 6.
Figure 7.Prevalence of obesity or type 2 diabetes in the first year of the study.
Stade de France Pharmacy